Abstract
Scope of Report
The scope of this report will primarily concentrate on the R&D competitive
landscape for Multiple Sclerosis (MS) from a clinical perspective.
This methodological approach is intended to provide insight into the strategic
opportunities and challenges, as well as the clinical hurdles facing MS drug
developers.
Specifically, the focus of our analysis is on the clinical trial design and
data results for compounds in phase II or beyond that have the potential to
alter the market dynamics in MS over the next 3-7 years.
What' s New in Volume II:
- Campath Phase 2 3-year data
- CDP-323 Phase 2 study design
- Teriflunomide Phase 3 study designs
- Laquinimod Phase 3 design
- MN-166 Phase 2 study results
- Rituxan Phase 2 RRMS study results
- Daclizumab Phase 2 study results
- CNTO-1275 Phase 1 study results
- BHT-3009 Safety Results
- AZD-9504 Product SnapShot & Preclinical data
View Cart
